Fact Check: Bharat Biotech's Covaxin approved for children above 12 years?
India | May 10, 2021, 12:37 PM ISTGovernment has said that a tweet claiming that Covaxin has been approved for children above 12 years of age is fake.
Government has said that a tweet claiming that Covaxin has been approved for children above 12 years of age is fake.
The company is supplying vaccines to Andhra Pradesh, Assam, Chhattisgarh, Gujarat, Jammu & Kashmir, Jharkhand, Madhya Pradesh, Odisha, Tamil Nadu, Telangana, Uttar Pradesh and West Bengal.
Serum Institute of India CEO Aadar Poonawalla has said that the production of COVID-19 vaccine Covishield is in full swing in Pune and he will review the operations once he is back in the country.
Covaxin vaccine maker Bharat Biotech on Thursday announced a drop in the price of its vaccine that will be made available to the state governments.
Maharashtra remains one of the worst-COVID-affected states in the country. As many as 66,358 new cases, 895 deaths and 67,752 recoveries were reported on Tuesday. The total case tally stands at 44,100,85.
The move has come days ahead of India's planned drive to inoculate all aged above 18. The vaccination drive is set to begin May 1.
Bharat Biotech has written to India's drug regulator seeking extension of the shelf-life of its indigenously developed COVID-19 vaccine Covaxin from six to 24 months, sources said on Sunday.
Covaxin, India's indigeniously developmed coronavirus vaccine, will be sold at Rs 600 per dose for state hospitals and Rs 1,200 per dose for private hospitals, vaccine maker Bharat Biotech has informed.
Govt Principal Secy (Covid Management and Vaccination) wrote letters to Bharat Biotech MD Krishna Yella and Serum Institute of India Limited CEO Adar Poonawalla in this regard.
The Biden administration has conveyed to India that they understand India's pharmaceutical requirements and has promised to review embargo on Covid-19 vaccine raw material.
COVID-19 vaccine: SII will supply 200 million doses and Bharat Biotech is to supply another 90 million doses to the government by July at a pre-agreed rate of Rs 150 per dose.
The expert panel of India's drug regulator, DCGI, has permitted Bharat Biotech to give the third dose of Covaxin to a few volunteers in its clinical trials of the COVID-19 vaccine.
Bharat Biotech had applied for emergency use authorisation for its vaccine candidate, Covaxin, in Nepal on January 13. Covaxin demonstrated an interim vaccine efficacy of 81 per cent in the Phase 3 clinical trials India.
The high court also asked the Centre to explain in affidavit the rationale behind keeping strict control over class of persons who can be vaccinated against COVID-19 currently as under the present system those above the age of 60 years or between 45 to 60 years with comorbidities can receive vaccination.
India's indigenously developed vaccine against coronavirus COVAXIN has demonstrated an interim vaccine efficacy of 81 per cent in its Phase 3 clinical trial. The trials involved 25,800 subjects, the largest ever conducted in India, in partnership with ICMR, informed vaccine maker Bharat Biotech.
Chinese and Russian-linked hacking campaigns in recent weeks targeted Indian vaccine makers Serum Institute of India (SII) and Bharat Biotech, cyber intelligence and threat discovery platform Cyfirma said on Monday.
Makers of Covaxin, Bharat Biotech has said that they can modify the vaccine against coronavirus South African variant within 15 days. Bharat Biotech's developed India's own vaccine Covaxin against Covid-19 and was rolled out on January 16.
Global healthcare company GSK, non-profit agency working to end health inequity PATH, and vaccine maker Bharat Biotech on Wednesday announced the signing of a product transfer agreement for malaria vaccine RTS,S/AS01E1.
Ninety-two countries have approached India for Covid-19 vaccines, bolstering New Delhi's credentials as the vaccine hub of the world.
Out of the 45 lakh doses, the city-based vaccine maker will be supplying over eight lakh to some of the friendly countries such as Mauritius, Philippines and Myanmar, free of cost as good will gesture sources added.
Top News